Using preliminary research to approve new treatments has high costs in morbidity and healthcare dollars, as Diana Zuckerman and colleagues outline
No takes yet. Share an insight, caveat, or question.
Zuckerman et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: